Bard set for Gore money soon as Q3 "solid"
This article was originally published in Clinica
Executive Summary
CR Bard had a “solid” third quarter, beating analyst expectations across all divisions and seeing margin expansion, noted Jefferies’ Raj Denhoy. Standout performances came in its vascular and surgical divisions, which saw sales of $209.9m (+4% year-on-year) and $118.1m (+10% year-on-year), versus analyst estimates of $199m and $115m, respectively. The former was driven by its Lutonix drug-eluting balloon, while the latter was helped by the surgical sealant contribution from Neomend, which Bard acquired last year (www.clinica.co.uk, 24 October 2012).
You may also be interested in...
Legal News In Brief
Enzo and Illumina settle patent battle; Bard and Gore argue over jury logistics for an upcoming trial; and former employee alleges False Claims Act violations by medical equipment maker Lincare.
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.